• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.

作者信息

Alexopoulos Dimitrios, Gkizas Vassilios, Patsilinakos Sotirios, Xanthopoulou Ioanna, Angelidis Christos, Anthopoulos Prodromos, Makris George, Perperis Angelos, Karanikas Stavros, Koutsogiannis Nikolaos, Davlouros Periklis, Deftereos Spyridon, Chiladakis John, Hahalis George

出版信息

J Am Coll Cardiol. 2013 Sep 3;62(10):940-1. doi: 10.1016/j.jacc.2013.05.021. Epub 2013 Jun 7.

DOI:10.1016/j.jacc.2013.05.021
PMID:23747780
Abstract
摘要

相似文献

1
Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI.替格瑞洛双倍负荷剂量与标准负荷剂量对比：接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者抗血小板作用的起效情况
J Am Coll Cardiol. 2013 Sep 3;62(10):940-1. doi: 10.1016/j.jacc.2013.05.021. Epub 2013 Jun 7.
2
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.随机评估替格瑞洛与普拉格雷在 ST 段抬高型心肌梗死患者中的抗血小板作用。
Circ Cardiovasc Interv. 2012 Dec;5(6):797-804. doi: 10.1161/CIRCINTERVENTIONS.112.972323. Epub 2012 Nov 20.
3
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.替格瑞洛双剂量（360 毫克）与标准剂量（60 毫克）普拉格雷负荷剂量在 ST 段抬高型心肌梗死患者中的比较：血小板抑制剂药物快速作用（RAPID）直接经皮冠状动脉介入治疗 2 期研究。
Am Heart J. 2014 Jun;167(6):909-14. doi: 10.1016/j.ahj.2014.03.011. Epub 2014 Apr 4.
4
Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention.替格瑞洛与氯吡格雷在直接经皮冠状动脉介入治疗中的安全性和有效性。
Heart. 2016 Apr;102(8):617-25. doi: 10.1136/heartjnl-2015-308963. Epub 2016 Feb 4.
5
Ticagrelor: the silence of the platelets.替格瑞洛：血小板的“沉默”。
Expert Opin Pharmacother. 2013 Feb;14(2):151-3. doi: 10.1517/14656566.2013.758252. Epub 2013 Jan 8.
6
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: Ready for prime time?ST段抬高型心肌梗死的院前替格瑞洛治疗：准备好进入黄金时代了吗？
Int J Cardiol. 2015 Sep 1;194:41-3. doi: 10.1016/j.ijcard.2015.05.064. Epub 2015 May 12.
7
How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS).氯吡格雷和替格瑞洛在接受直接经皮冠状动脉介入治疗的患者中抑制血小板需要多长时间？一项详细的药效学分析：ST段抬高型心肌梗死血小板反应性的时间进程（TOPS）。
Semin Thromb Hemost. 2017 Jun;43(4):439-446. doi: 10.1055/s-0037-1599156. Epub 2017 Apr 4.
8
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.强化抑制P2Y12介导的血小板聚集对接受经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的临床影响。
Hosp Pract (1995). 2010 Nov;38(4):38-43. doi: 10.3810/hp.2010.11.338.
9
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.普拉格雷和替格瑞洛负荷剂量在 ST 段抬高型心肌梗死患者中的比较：RAPID（血小板抑制剂药物快速激活）直接经皮冠状动脉介入治疗研究。
J Am Coll Cardiol. 2013 Apr 16;61(15):1601-6. doi: 10.1016/j.jacc.2013.01.024. Epub 2013 Mar 22.
10
Personalized ADP-receptor inhibition strategy and outcomes following primary PCI for STEMI (PASTOR study).ST段抬高型心肌梗死直接经皮冠状动脉介入治疗后的个性化ADP受体抑制策略及结果（PASTOR研究）
Int J Cardiol. 2016 Jan 1;202:463-6. doi: 10.1016/j.ijcard.2015.09.074. Epub 2015 Sep 25.

引用本文的文献

1
Testing P2Y12 platelet inhibitors generics beyond bioequivalence: a parallel single-blinded randomized trial.超出生物等效性范围测试P2Y12血小板抑制剂仿制药：一项平行单盲随机试验。
Thromb J. 2022 Aug 17;20(1):44. doi: 10.1186/s12959-022-00405-y.
2
Modified ticagrelor loading doses according to the vasodilator-stimulated phosphoprotein phosphorylation index improve the clinical outcome in ST-elevation myocardial infarction patients with high on-treatment platelet reactivity.根据血管扩张刺激磷蛋白磷酸化指数调整替卡格雷洛负荷剂量可改善高血小板反应性的 ST 段抬高型心肌梗死患者的临床转归。
Cardiol J. 2023;30(5):771-780. doi: 10.5603/CJ.a2021.0105. Epub 2021 Sep 28.
3
Long-term pharmacodynamic effects of Ticagrelor versus Clopidogrel in fibrinolytic-treated STEMI patients undergoing early PCI.
溶栓治疗后行早期 PCI 的 STEMI 患者中替格瑞洛与氯吡格雷的长期药效学影响。
J Thromb Thrombolysis. 2018 Feb;45(2):225-233. doi: 10.1007/s11239-017-1581-2.
4
Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing.靶内微剂量给药（ITM）：一种旨在实现将生物学见解更安全、更早期地转化为人体试验的新型药物开发方法。
Clin Transl Sci. 2017 Sep;10(5):337-350. doi: 10.1111/cts.12464. Epub 2017 Apr 18.
5
Antithrombotic therapy for patients with STEMI undergoing primary PCI.ST段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗的抗栓治疗。
Nat Rev Cardiol. 2017 Jun;14(6):361-379. doi: 10.1038/nrcardio.2017.18. Epub 2017 Feb 23.
6
Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients.阿昔单抗作为一种桥接策略，用于克服ST段抬高型心肌梗死（STEMI）患者中吗啡与普拉格雷的相互作用。
Br J Clin Pharmacol. 2016 Nov;82(5):1343-1350. doi: 10.1111/bcp.13053. Epub 2016 Jul 24.
7
Design and Rationale of the APELOT Trial: A Randomized, Open-Label, Multicenter, Phase IV Study to Evaluate the Antiplatelet Effect of Different Loading Dose of Ticagrelor in Patients With Non-ST Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.APELOT试验的设计与原理：一项随机、开放标签、多中心、IV期研究，旨在评估替格瑞洛不同负荷剂量对接受经皮冠状动脉介入治疗的非ST段抬高急性冠状动脉综合征患者的抗血小板作用。
Medicine (Baltimore). 2016 May;95(22):e3756. doi: 10.1097/MD.0000000000003756.
8
Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.替格瑞洛片碾碎与完整服用在ST段抬高型心肌梗死患者中的对比：一项随机药代动力学/药效学研究
Clin Pharmacokinet. 2016 Mar;55(3):359-67. doi: 10.1007/s40262-015-0320-0.
9
Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update.替格瑞洛：药代动力学、药效学和药物遗传学概况：最新进展
Clin Pharmacokinet. 2015 Nov;54(11):1125-38. doi: 10.1007/s40262-015-0290-2.
10
Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis.替格瑞洛与高剂量氯吡格雷用于溶栓后血小板高反应性的ST段抬高型心肌梗死患者的比较
J Thromb Thrombolysis. 2015 Oct;40(3):261-7. doi: 10.1007/s11239-015-1183-9.